Cocrystal Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
05. Januar 2021 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma, Inc. Announces License Agreement with Kansas State University Research Foundation for Norovirus and Coronavirus Antiviral Compounds
24. Februar 2020 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Feb. 24, 2020 (GLOBE NEWSWIRE) -- - Company acquires rights to preclinical leads for Norovirus and Coronavirus therapeutics - - Proprietary platform technology will be used to...
Cocrystal Pharma Inc. to Present at Noble Capital Markets’ 16th Annual Investor Conference
11. Februar 2020 08:35 ET
|
Cocrystal Pharma, Inc.
– Presentation on Tuesday, February 18th at 11:30 AM ET – BOTHELL, WA, Feb. 11, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage...
COCRYSTAL PHARMA, INC. PRICES $3,000,000 UNDERWRITTEN PUBLIC OFFERING
31. Oktober 2019 09:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Oct. 31, 2019 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral...
COCRYSTAL PHARMA, INC. ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK
30. Oktober 2019 16:45 ET
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Oct. 30, 2019 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral...
Cocrystal Pharma Provides Update on Clinical Development Program Evaluating CC-31244 for Ultra-Short Treatment of Hepatitis C Virus
22. Januar 2019 08:00 ET
|
Cocrystal Pharma, Inc.
- Hepatitis C program designed to develop ultra-short treatment for hepatitis C virus (HCV) consisting of CC-31244, an oral, potent, broad-spectrum non-nucleoside inhibitor, as a part of combination...
Cocrystal Pharma Completes Patient Enrollment in Phase 2a Study Evaluating CC-31244 for Ultra-Short Treatment of Hepatitis C
20. September 2018 08:00 ET
|
Cocrystal Pharma, Inc.
ATLANTA, GA and BOTHELL, WA, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and...
Cocrystal Pharma Reports 2018 Second Quarter Financial Results and Provides Corporate Update
09. August 2018 08:00 ET
|
Cocrystal Pharma, Inc.
– First half of 2018 marked by management’s successful execution of corporate, clinical and regulatory strategies – – Topline results from Phase 2a study evaluating CC-31244 for...
Cocrystal Pharma Commences Enrollment and Initiates Patient Dosing in Phase 2a Study Evaluating CC-31244 for the Treatment of HCV
28. Juni 2018 07:35 ET
|
Cocrystal Pharma, Inc.
- Topline results from Phase 2a study expected to be announced before year end - ATLANTA, GA and BOTHELL, WA, June 28, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal”...
Cocrystal Pharma Announces Inclusion in Russell Microcap® Index
25. Juni 2018 08:00 ET
|
Cocrystal Pharma, Inc.
ATLANTA, GA and BOTHELL, WA, June 25, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and...